Pilot Study of Neoadjuvant Treatment with Erlotinib in Nonmetastatic Head and Neck Squamous Cell Carcinoma
Fabienne Thomas(Institut Claudius Regaud), Jean‐Pierre Delord, A. Benlyazid(Institut Claudius Regaud), Ben Allal(Université Toulouse III - Paul Sabatier), Jérôme Sarini(Institut Claudius Regaud), F. Courbon(Institut Claudius Regaud), Jean Louis Lefèbvre(Centre Oscar Lambret), Étienne Chatelut(Université Toulouse III - Paul Sabatier), M. Rives(Centre Hospitalier Universitaire de Nantes), Philippe Rochaix
Cited by 71
Related Papers
Defining risk levels in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501)
|Head & Neck|2005|1.8k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies
|Journal of Thoracic Oncology|2019|437
Induction Chemotherapy Followed by Either Chemoradiotherapy or Bioradiotherapy for Larynx Preservation: The TREMPLIN Randomized Phase II Study
|Journal of Clinical Oncology|2013|418
PD-1 Blockade in Anaplastic Thyroid Carcinoma
|Journal of Clinical Oncology|2020|349